SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GelTex Pharmaceuticals (GELX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert L. Ray who wrote (53)6/23/1998 9:54:00 PM
From: H. Bradley Toland, Jr.  Read Replies (1) of 127
 
Yeah, I'm still out here; waiting. Looks to me as if the stock has just about finished changing hands, weak hands to strong hands. I base this on the positive price volume action over the past few months.

I do not agree with your point about RenaGel being fully priced in the stock. It may be a $150 million product (rev) to Geltex in the U.S. alone. And the ramp up should be fast.

CholestaGel could be a blockbuster product.

Me thinks the stock is very cheap with a $340 million valuation. Stay tuned.

Brad
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News